Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977468 · ClinicalTrials.gov registry record · Phase 1
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
A Phase 1 study of Triple Negative Breast Cancer, sponsored by Eileen Connolly.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT02977468 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Eileen Connolly. The registered enrollment target is 15 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02977468, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Eileen Connolly.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.
Conditions Studied
Interventions
- DRUG Merck 3475 Pembrolizumab
- RADIATION Intraoperative radiation therapy (IORT)
Study Locations (3)
Georgia
- Emory University - Atlanta
Illinois
- Loyola University Chicago - Maywood
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02977468
The ClinicalTrials.gov registry entry for NCT02977468 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Eileen Connolly, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Merck 3475 Pembrolizumab is the first listed.
NCT02977468 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT02977468 about?
NCT02977468 is a clinical study titled "Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer". Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in n...
What is the current status of trial NCT02977468?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-10-25. Estimated completion is 2025-12-31.
What conditions does trial NCT02977468 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02977468?
The interventions under investigation include: Merck 3475 Pembrolizumab (DRUG), Intraoperative radiation therapy (IORT) (RADIATION).
Who is sponsoring clinical trial NCT02977468?
This trial is sponsored by Eileen Connolly, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02977468 being conducted?
This trial has 3 study locations across Georgia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.